BRIEF published on 09/16/2026 at 07:35, 2 days ago Sensorion is considering an initial public offering in the United States Biotechnology Initial Public Offering DRY Sensory Auditory Therapies
BRIEF published on 09/16/2026 at 07:35, 2 days ago Sensorion Submits Initial Public Offering Draft Biotechnology IPO SEC Filing Audiology Sensorion
PRESS RELEASE published on 09/16/2026 at 07:30, 2 days 1 hour ago Inside Information / Other news releases Sensorion announces submission of draft registration statement to SEC for potential U.S. IPO. Company focuses on novel therapies for hearing loss disorders SEC Sensorion Hearing Loss Therapies Draft Registration Statement U.S. IPO
BRIEF published on 09/15/2026 at 07:35, 3 days ago Sensorion Completes Reverse Share Split Biotechnology Shareholder Compensation Reverse Share Split Hearing Loss Therapies Euronext Growth Market
PRESS RELEASE published on 09/15/2026 at 07:30, 3 days 1 hour ago Inside Information / Other news releases Sensorion completes reverse share split, exchanging 50 existing shares for 1 new share with €5 par value. New shares listed on Euronext Growth market in Paris under ISIN code FR001401A9Z0 Shareholder Compensation ISIN Code Reverse Share Split Sensorion Euronext Growth Market
BRIEF published on 09/03/2026 at 07:35, 15 days ago Sensorion receives authorization to initiate a clinical trial in France Gene Therapy Clinical Trial France Hearing Sensory
BRIEF published on 09/03/2026 at 07:35, 15 days ago Sensorion Receives Approval for SENS-601 Trial in France Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-601
PRESS RELEASE published on 09/03/2026 at 07:30, 15 days 1 hour ago Inside Information / Other news releases Sensorion receives approval from ANSM to start Phase I/II clinical trial of SENS-601, a gene therapy for GJB2-related hearing loss in France. Event hosted to discuss program details Gene Therapy Clinical Trial Sensorion SENS-601 GJB2-related Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 3 months 8 days ago Sensorion Advances SENS-601 for GJB2-Related Hearing Loss Clinical Trials Gene Therapy Sensorion SENS-601 GJB2 Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 3 months 8 days ago Sensorion Refocuses on SENS-601 for Gene Therapy Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
Published on 09/18/2026 at 06:30, 2 hours 4 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 7 hours 39 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 8 hours 9 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 10 hours 19 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/18/2026 at 08:10, 24 minutes ago NORMA Group successfully completes second public share buyback offer with a repurchase volume of approximately EUR 208 million
Published on 09/18/2026 at 08:05, 29 minutes ago THE TOKYO PASS Renews Official Website, Redefining Wellness Tourism in Tokyo with "Museum Bathing (R)"
Published on 09/17/2026 at 17:40, 14 hours 54 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 14 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days 1 hour ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
